HRP20201651T1 - Uporaba cd24 za snižavanje razina lipoproteina niske gustoće kolesterola - Google Patents
Uporaba cd24 za snižavanje razina lipoproteina niske gustoće kolesterola Download PDFInfo
- Publication number
- HRP20201651T1 HRP20201651T1 HRP20201651TT HRP20201651T HRP20201651T1 HR P20201651 T1 HRP20201651 T1 HR P20201651T1 HR P20201651T T HRP20201651T T HR P20201651TT HR P20201651 T HRP20201651 T HR P20201651T HR P20201651 T1 HRP20201651 T1 HR P20201651T1
- Authority
- HR
- Croatia
- Prior art keywords
- protein
- use according
- ldl
- subject
- human
- Prior art date
Links
- 108010028554 LDL Cholesterol Proteins 0.000 title 1
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 claims 25
- 102100038081 Signal transducer CD24 Human genes 0.000 claims 23
- 102000004169 proteins and genes Human genes 0.000 claims 8
- 108090000623 proteins and genes Proteins 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 102000007330 LDL Lipoproteins Human genes 0.000 claims 2
- 108010007622 LDL Lipoproteins Proteins 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 102000044489 human CD24 Human genes 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/323—Arteriosclerosis, Stenosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Endocrinology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
Claims (15)
1. CD24 protein za uporabu u smanjenju razine lipoproteina niske gustoće (LDL) kolesterola (LDL-C) kod subjekta.
2. CD24 protein za uporabu prema patentnom zahtjevu 1, naznačen time što subjekt ima povišenu razinu LDL-C.
3. CD24 protein za uporabu prema patentnom zahtjevu 2, naznačen time što subjekt ima razinu LDL-C veću od ili jednaku 75 mg/dL, ili razinu LDL-C veću od ili jednaku 70 mg/dL ili 190 mg/dL.
4. CD24 protein za uporabu prema patentnom zahtjevu 1, naznačen time što je subjekt prethodno liječen drugim lijekom za snižavanje LDL-C, pri čemu drugi lijek za snižavanje LDL-C nije CD24 protein.
5. CD24 protein za uporabu prema patentnom zahtjevu 4, naznačen time što je drugi lijek za snižavanje LDL-C statin ili antagonist PCSK9.
6. CD24 protein naznačen time što je za uporabu za liječenje ili prevenciji ateroskleroze ili za smanjenje rizika od aterosklerotske kardiovaskularne bolesti kod subjekta.
7. CD24 protein za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time što CD24 protein sadrži zreli humani CD24 polipeptid ili njegovu varijantu.
8. CD24 protein za uporabu prema patentnom zahtjevu 7, naznačen time što zreli humani CD24 polipeptid sadrži sekvencu odabranu iz skupine koja se sastoji od sekvenci navedenih u SEQ ID NO: 1 i 2.
9. CD24 protein za uporabu prema patentnom zahtjevu 7 ili 8, naznačen time što CD24 protein nadalje sadrži proteinsku oznaku, pri čemu je proteinska oznaka kondenzirana na N-terminalnom kraju ili C-terminalnom kraju CD24 proteina.
10. CD24 protein za uporabu prema patentnom zahtjevu 9, naznačen time što proteinska oznaka sadrži Fc regiju proteina imunoglobulina (Ig) sisavaca.
11. CD24 protein za uporabu prema patentnom zahtjevu 10, naznačen time što je Ig protein sisavaca humani Ig protein, i pri čemu Fc regija sadrži: (a) zglobnu regiju i CH2 i CH3 domene humanog Ig proteina, i pri čemu je humani Ig protein odabran iz skupine koja se sastoji od IgG1, IgG2, IgG3, IgG4, i IgA; ili, (b) zglobnu regiju i CH2, CH3 i CH4 domene humanog IgM.
12. CD24 protein za uporabu prema patentnom zahtjevu 11, naznačen time što CD24 protein sadrži sekvencu navedenu u SEQ ID NO: 6, 11, ili 12.
13. CD24 protein za uporabu prema bilo kojem od patentnih zahtjeva 1-6, naznačen time što se sekvenca CD24 proteina sastoji od sekvence navedene u SEQ ID NO: 6, 11 ili 12.
14. CD24 protein za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time što je CD24 protein topljiv.
15. CD24 protein za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time što je CD24 protein glikoziliran.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562158157P | 2015-05-07 | 2015-05-07 | |
| EP16790128.9A EP3292144B1 (en) | 2015-05-07 | 2016-05-06 | Use of cd24 for lowering low-density lipoprotein cholesterol levels |
| PCT/US2016/031109 WO2016179456A1 (en) | 2015-05-07 | 2016-05-06 | Use of cd24 for lowering low-density lipoprotein cholesterol levels |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201651T1 true HRP20201651T1 (hr) | 2020-12-25 |
Family
ID=57218627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201651TT HRP20201651T1 (hr) | 2015-05-07 | 2020-10-14 | Uporaba cd24 za snižavanje razina lipoproteina niske gustoće kolesterola |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10369197B2 (hr) |
| EP (1) | EP3292144B1 (hr) |
| JP (1) | JP6751756B2 (hr) |
| KR (1) | KR20170141216A (hr) |
| CN (1) | CN107531772B (hr) |
| AU (1) | AU2016258084B2 (hr) |
| BR (1) | BR112017022394A2 (hr) |
| CA (1) | CA2982612A1 (hr) |
| EA (1) | EA038520B1 (hr) |
| ES (1) | ES2829235T3 (hr) |
| HK (1) | HK1249521A1 (hr) |
| HR (1) | HRP20201651T1 (hr) |
| HU (1) | HUE051866T2 (hr) |
| IL (1) | IL255086B (hr) |
| MX (1) | MX2017014095A (hr) |
| PT (1) | PT3292144T (hr) |
| WO (1) | WO2016179456A1 (hr) |
| ZA (1) | ZA201706846B (hr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3292144T (pt) * | 2015-05-07 | 2020-11-05 | Oncoimmune Inc | Utilização de cd24 para reduzir os níveis de colesterol de lipoproteína de baixa densidade |
| SG11201908077XA (en) | 2017-03-07 | 2019-09-27 | Oncoimmune Inc | Methods of use of soluble cd24 for treating systemic lupus erythematosus |
| US20190248881A1 (en) * | 2017-12-04 | 2019-08-15 | Precithera, Inc. | TGF-ß RECEPTOR FUSION PROTEINS AND OTHER TGF-ß ANTAGONISTS FOR REDUCING TGF-ß SIGNALING |
| US20210046154A1 (en) * | 2018-03-05 | 2021-02-18 | Oncoimmune, Inc | Methods of use of soluble cd24 for treating acquired immune deficiency syndrome (hiv/aids) |
| CA3102374A1 (en) * | 2018-06-04 | 2019-12-12 | Oncoimmune, Inc. | Methods of use of cd24 for the prevention and treatment of leukemia relapse |
| US20220000973A1 (en) * | 2019-02-06 | 2022-01-06 | Oncolmmune, Inc. | Targeting CD24-Siglec Interactions for the Treatment and Prevention of Nonalcoholic Steatohepatitis |
| WO2020163523A2 (en) * | 2019-02-06 | 2020-08-13 | Oncoimmune, Inc. | Targeting cd24-siglec interactions for treating subjects with prediabetes or diabetes |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6544566B1 (en) * | 1999-04-23 | 2003-04-08 | Protein Technologies International, Inc. | Composition containing plant sterol, soy protein and isoflavone for reducing LDL cholesterol |
| AU2001259792B2 (en) * | 2000-03-29 | 2005-12-22 | The Ohio State University Research Foundation | Methods of blocking tissue destruction by autoreactive T cells |
| CN1981772A (zh) * | 2000-05-13 | 2007-06-20 | 阿彻-丹尼尔斯-米德兰公司 | 降低低密度脂蛋白胆固醇浓度的组合物和方法 |
| EP2231184A4 (en) * | 2007-12-21 | 2012-02-15 | Univ Rochester | CD24 AS A STEM CELL MARKER FOR BRAIN TUMOR AND DIAGNOSTIC AND THERAPEUTIC TARGET MOLECULAR IN PRIMARY NEURONAL AND GLIAL BRAIN TUMORS |
| US8163281B2 (en) * | 2009-03-04 | 2012-04-24 | The Regents Of The University Of Michigan | Treatment of drug-related side effect and tissue damage by targeting the CD24-HMGB1-Siglec10 axis |
| US8354520B2 (en) * | 2009-12-10 | 2013-01-15 | Kaohsiung Medical University | Composition and method for treating atherosclerosis, method for determining if a subject has atherosclerosis and method of screening an anti-atherosclerotic drug |
| US20130231464A1 (en) * | 2010-04-28 | 2013-09-05 | Oncolmmune, Inc. | Methods of use of soluble cd24 for therapy of rheumatoid arthritis |
| CN102869369B (zh) * | 2010-04-28 | 2016-05-18 | 肿瘤免疫股份有限公司 | 利用可溶性cd24治疗类风湿性关节炎的方法 |
| CN104039134A (zh) * | 2011-06-10 | 2014-09-10 | 宾夕法尼亚大学董事会 | 细胞组学血管健康概况分析的系统和方法 |
| PT3292144T (pt) * | 2015-05-07 | 2020-11-05 | Oncoimmune Inc | Utilização de cd24 para reduzir os níveis de colesterol de lipoproteína de baixa densidade |
-
2016
- 2016-05-06 PT PT167901289T patent/PT3292144T/pt unknown
- 2016-05-06 EA EA201792418A patent/EA038520B1/ru unknown
- 2016-05-06 BR BR112017022394A patent/BR112017022394A2/pt not_active IP Right Cessation
- 2016-05-06 CA CA2982612A patent/CA2982612A1/en not_active Abandoned
- 2016-05-06 JP JP2018510322A patent/JP6751756B2/ja not_active Expired - Fee Related
- 2016-05-06 ES ES16790128T patent/ES2829235T3/es active Active
- 2016-05-06 HU HUE16790128A patent/HUE051866T2/hu unknown
- 2016-05-06 WO PCT/US2016/031109 patent/WO2016179456A1/en active Application Filing
- 2016-05-06 AU AU2016258084A patent/AU2016258084B2/en not_active Ceased
- 2016-05-06 MX MX2017014095A patent/MX2017014095A/es unknown
- 2016-05-06 KR KR1020177032235A patent/KR20170141216A/ko not_active Application Discontinuation
- 2016-05-06 CN CN201680026449.2A patent/CN107531772B/zh not_active Expired - Fee Related
- 2016-05-06 EP EP16790128.9A patent/EP3292144B1/en active Active
- 2016-05-06 US US15/572,330 patent/US10369197B2/en not_active Expired - Fee Related
-
2017
- 2017-10-10 ZA ZA2017/06846A patent/ZA201706846B/en unknown
- 2017-10-17 IL IL255086A patent/IL255086B/en unknown
-
2018
- 2018-06-21 HK HK18107984.3A patent/HK1249521A1/zh unknown
-
2019
- 2019-06-17 US US16/443,498 patent/US11026995B2/en active Active
-
2020
- 2020-10-14 HR HRP20201651TT patent/HRP20201651T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA038520B1 (ru) | 2021-09-09 |
| AU2016258084A1 (en) | 2017-11-02 |
| JP6751756B2 (ja) | 2020-09-09 |
| EP3292144B1 (en) | 2020-08-26 |
| US10369197B2 (en) | 2019-08-06 |
| JP2018515605A (ja) | 2018-06-14 |
| AU2016258084B2 (en) | 2020-01-30 |
| HUE051866T2 (hu) | 2021-03-29 |
| EP3292144A4 (en) | 2018-11-14 |
| US11026995B2 (en) | 2021-06-08 |
| ES2829235T3 (es) | 2021-05-31 |
| US20180110828A1 (en) | 2018-04-26 |
| EA201792418A1 (ru) | 2018-02-28 |
| CN107531772B (zh) | 2021-09-21 |
| KR20170141216A (ko) | 2017-12-22 |
| US20190307841A1 (en) | 2019-10-10 |
| CN107531772A (zh) | 2018-01-02 |
| IL255086B (en) | 2021-08-31 |
| WO2016179456A1 (en) | 2016-11-10 |
| EP3292144A1 (en) | 2018-03-14 |
| ZA201706846B (en) | 2018-12-19 |
| PT3292144T (pt) | 2020-11-05 |
| HK1249521A1 (zh) | 2018-11-02 |
| BR112017022394A2 (pt) | 2018-07-17 |
| CA2982612A1 (en) | 2016-11-10 |
| IL255086A0 (en) | 2017-12-31 |
| MX2017014095A (es) | 2018-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201651T1 (hr) | Uporaba cd24 za snižavanje razina lipoproteina niske gustoće kolesterola | |
| WO2016081746A3 (en) | Antibodies comprising modified heavy constant regions | |
| RS52888B (en) | COMBINATION OF BLYS INHIBITION AND MYPHOPHENOLATE MOFETILE FOR THE TREATMENT OF AUTOMMUNE DISEASE | |
| PH12019502356A1 (en) | Trem2 antigen binding proteins and uses thereof | |
| WO2018218056A8 (en) | ANTIBODIES COMPRISING MODIFIED HEAVY CHAIN CONSTANT CHAIN REGIONS | |
| EP3991748A3 (en) | Anti-sortilin antibodies and methods of use thereof | |
| CY1123307T1 (el) | Πρωτεϊνες συγχωνευσης fgf21 μακρας δρασης και φαρμακευτικες συνθεσεις που τις περιλαμβανουν | |
| WO2006110214A3 (en) | Antibodies against mammalian metapneumovirus | |
| JP2018531914A5 (hr) | ||
| ATE513563T1 (de) | Therapeutische und toleranz-induzierende antikörper | |
| EA201291181A1 (ru) | Композиции и способы применения терапевтических поливалентных антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6) | |
| BRPI0614040B8 (pt) | anticorpo isolado que se liga especificamente a b7rp1, polipeptídeo, composição farmacêutica, vetor de expressão, célula hospedeira, linhagem celular isolada e métodos para a detecção de b7rp1 em uma amostra biológica e de produção de um anticorpo ou polipeptídeo | |
| UA116871C2 (uk) | СПОСІБ ЛІКУВАННЯ МІЄЛОДИСПЛАСТИЧНОГО СИНДРОМУ, ТАЛАСЕМІЇ ТА СЕРПОПОДІБНО-КЛІТИННОЇ АНЕМІЇ ЗА ДОПОМОГОЮ ЗАСТОСУВАННЯ АНТАГОНІСТА АКТИВІНУ ПОЛІПЕПТИДУ ActRII | |
| PE20211272A1 (es) | POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO | |
| UY32279A (es) | Composiciones estables de anticuerpos y métodos para estabilizarlas | |
| EA201100546A1 (ru) | Полипептиды, вариабельные домены антител и антагонисты | |
| ES2633597T3 (es) | Anticuerpos con afinidad modificada para FcRn que promueven la eliminación del antígeno | |
| WO2008121615A3 (en) | Antibody formulation | |
| DK2371391T3 (da) | Terapeutisk anvendelse af anti-CS1-antistoffer | |
| PE20081899A1 (es) | Anticuerpos anti-ige | |
| TR200102733T2 (tr) | IL-18 kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri | |
| BR112013008407A2 (pt) | antígenos de clostridium difficile | |
| WO2011002968A3 (en) | Polypeptides and method of treatment | |
| EA201300133A1 (ru) | Фармацевтическая композиция и способ лечения ожирения, сопутствующих метаболических расстройств и зависимости от психоактивных веществ | |
| NO20014131L (no) | Epitoper eller mimotoper avledet fra C-epsilon-3- eller C- epsilon-4-domener fra IgE, antagonister derav og deresterapeutiske anvendelser |